Lucerastat
Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS) . Lucerastat has the potential for Fabry disease study[1][2].
Product Specifications
CAS Number
141206-42-0
Product Name Alternative
NB-DGJ; N- (n-Butyl) deoxygalactonojirimycin
UNSPSC
12352005
Hazard Statement
H315, H319
Target
Glucosylceramide Synthase (GCS)
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/lucerastat.html
Purity
98.0
Solubility
DMSO : 22 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 24 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O
Molecular Formula
C10H21NO4
Molecular Weight
219.28
Precautions
H315, H319
References & Citations
[1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.|[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
16415061 1.0 µg DNA
CMD2A Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details